Example of some research summary in cardiology conference are as follows:
2006 March 11 -14th at American College of Cardiology- Atlanta Georgia
During the 55th Annual Scientific Session of the American College of Cardiology
Based on Recent analysis from the PEECH (Prospective Evaluation of ECP therapy) trial in patients who have advanced coronary disease, including those with heart failure.
George A. Beller, MD, FACC, Ruth C. Heede Professor in Cardiology, University of Virginia Health System, presented a comprehensive review of data supporting the use of ECP therapy in patients with who have advanced ischemic heart disease, including those with heart failure but few or no options for treatment.
The presentations illustrated ECP(R) therapy’s leading role in the treatment of His talk included recent analysis from the PEECH (Prospective Evaluation of ECP in Congestive Heart Failure) trial demonstrating that patients age sixty-five and older had a more robust response to ECP therapy compared to the overall population in the trial. Patients age sixty-five and older improved significantly on both the primary end-points of exercise duration and peak oxygen uptake assessed in the PEECH study and showed a greater increase in their ability to exercise relative to the overall study population, suggesting that Medicare-eligible heart failure patients are more likely to benefit from the treatment.
In a separate presentation, Ozlem Soran, MD, MPH, FACC, FESC, Associate Professor of Medicine, University of Pittsburgh Medical Center, presented data showing a 91% reduction in emergency room visits and an 86% reduction in hospitalizations over a six-month period following ECP therapy
Additionally, a presentation by William Lawson, MD, FACC, Professor of Clinical Medicine, Stony Brook University, of New York, highlighted improvements of ECP therapy , while another by Timothy Henry, MD, FACC, University of Minnesota, Minneapolis Heart Institute Foundation, showed that angina patients with a history of peripheral arterial disease can be safely treated and benefit from the therapy, showing improvements in endothelial function obtained with the therapy.
2006 August 29th – WESTBURY, New York
Positive PEECH Trial Results and Related Article Highlighting Mechanism of Action Published in the Journal of the American College of Cardiology
Arthur Feldman, M.D., Ph.D., professor and chairman of the Department of Medicine, Jefferson Medical College, Thomas Jefferson University, and principal investigator for the PEECH trial noted, “Results of the PEECH trial, specifically the greater benefit observed in ischemic heart failure patients, are consistent with prior studies of ECP in patients with ischemic heart disease, including a randomized trial in angina. In stable, well-managed heart failure patients who remain symptomatic despite receiving guideline-recommended therapy, ECP can help by relieving symptoms, increasing activity levels and improving quality of life in this difficult-to-treat disease.”
Simultaneously, researchers at the University of Florida College of Medicine reported that ECP therapy reduced arterial stiffness and decreased wasted cardiac energy in patients with long-standing coronary artery disease and ischemia. The report, entitled “Enhanced External Counterpulsation Treatment Improves Arterial Wall Properties and Wave Reflection Characteristics in Patients With Refractory Angina,” illustrates important favorable effects ECP therapy achieves on blood vessels outside of the heart and reveals one of the mechanisms by which both angina and ischemic heart failure patients obtain benefit.
2006 September 10th -13th at the 10th Annual Heart Failure Society of America Scientific (HFSA) Meeting held in Seattle, Washington
Investigators at the Escorts Heart Institute and Research Centre, New Delhi, India, presented data demonstrating that heart failure patients were able to double their exercise capacity following a course of ECP therapy and maintain the benefit at one-year follow-up. Dr. Anil K. Gothwal and colleagues also used echocardiography to objectively assess function and size of the heart’s main pumping chamber, the left ventricle, showing significant improvement and confirming some of the physiologic changes achievable with ECP therapy.
Susan F. Neill, Citrus Cardiology Consultants, Inverness, FL, and Dr. Michael E. McIvor, St. Petersburg Heart Center, St. Petersburg, FL, presented data from a cohort of 53 adult patients with systolic heart failure. Their results also showed significant improvements in symptom status, exercise capacity, quality of life and ventricular function. Moreover, circulating levels of BNP (brain natriuretic peptide), a marker of heart failure progression, were also shown to significantly improve upon completion of therapy.
William Lawson, M.D., FACC, University of Stony Brook Medical Center, Stony Brook, NY, presented data from the International ECP Patient Registry demonstrating that ECP therapy is equally effective in diabetic and non-diabetic patients suffering from angina and heart failure. Both diabetic and non-diabetic heart failure patients received the same benefits from ECP treatment, with improvement in at least one class in both Canadian Cardiovascular Society (CCS) and New York Heart Association (NYHA) classifications, decreases in weekly angina episodes and nitroglycerin use, and improvement in quality of life scores.